Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 5 | 2018 | 304 | 1.950 |
Why?
|
| Laparoscopy | 12 | 2022 | 771 | 1.730 |
Why?
|
| Proctocolectomy, Restorative | 10 | 2022 | 88 | 1.490 |
Why?
|
| Rectal Neoplasms | 4 | 2021 | 127 | 1.240 |
Why?
|
| Rectum | 4 | 2018 | 148 | 1.240 |
Why?
|
| Inflammatory Bowel Diseases | 9 | 2021 | 575 | 1.070 |
Why?
|
| Colitis, Ulcerative | 10 | 2022 | 736 | 1.050 |
Why?
|
| Robotics | 3 | 2018 | 269 | 0.920 |
Why?
|
| Colon | 3 | 2018 | 509 | 0.880 |
Why?
|
| Crohn Disease | 9 | 2022 | 758 | 0.850 |
Why?
|
| Colonic Pouches | 6 | 2022 | 68 | 0.840 |
Why?
|
| Anastomotic Leak | 4 | 2018 | 103 | 0.770 |
Why?
|
| Colectomy | 6 | 2022 | 172 | 0.740 |
Why?
|
| Learning Curve | 2 | 2018 | 19 | 0.730 |
Why?
|
| Colorectal Neoplasms | 5 | 2022 | 981 | 0.670 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 126 | 0.580 |
Why?
|
| Credentialing | 1 | 2017 | 14 | 0.580 |
Why?
|
| Rectovaginal Fistula | 1 | 2016 | 7 | 0.550 |
Why?
|
| Surgical Flaps | 2 | 2016 | 249 | 0.550 |
Why?
|
| Rectus Abdominis | 1 | 2015 | 40 | 0.510 |
Why?
|
| Anal Canal | 2 | 2016 | 88 | 0.500 |
Why?
|
| Intestinal Mucosa | 2 | 2016 | 805 | 0.470 |
Why?
|
| Leiomyosarcoma | 1 | 2014 | 45 | 0.450 |
Why?
|
| Postoperative Complications | 10 | 2022 | 2275 | 0.450 |
Why?
|
| Intestines | 2 | 2015 | 416 | 0.410 |
Why?
|
| Pouchitis | 2 | 2021 | 44 | 0.350 |
Why?
|
| Retrospective Studies | 20 | 2022 | 9003 | 0.340 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 201 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 967 | 0.310 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1194 | 0.310 |
Why?
|
| Humans | 41 | 2022 | 89063 | 0.300 |
Why?
|
| Quality of Life | 2 | 2019 | 1662 | 0.290 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 461 | 0.290 |
Why?
|
| Gastrointestinal Agents | 2 | 2019 | 171 | 0.280 |
Why?
|
| Neutrophils | 2 | 2006 | 308 | 0.260 |
Why?
|
| Focal Adhesions | 3 | 2017 | 70 | 0.260 |
Why?
|
| Treatment Outcome | 10 | 2020 | 8203 | 0.250 |
Why?
|
| Anastomosis, Surgical | 3 | 2022 | 273 | 0.240 |
Why?
|
| Fibronectins | 2 | 2006 | 101 | 0.230 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2003 | 16 | 0.230 |
Why?
|
| Adult | 20 | 2020 | 26507 | 0.230 |
Why?
|
| Integrin beta1 | 1 | 2003 | 33 | 0.230 |
Why?
|
| Candidiasis | 1 | 2003 | 37 | 0.220 |
Why?
|
| Male | 23 | 2021 | 42251 | 0.220 |
Why?
|
| Hypoalbuminemia | 1 | 2022 | 9 | 0.220 |
Why?
|
| NADPH Oxidases | 1 | 2003 | 82 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2020 | 699 | 0.210 |
Why?
|
| Malnutrition | 1 | 2022 | 32 | 0.210 |
Why?
|
| Pressure Ulcer | 1 | 2022 | 42 | 0.210 |
Why?
|
| Operative Time | 3 | 2018 | 142 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2003 | 184 | 0.200 |
Why?
|
| Female | 21 | 2020 | 46011 | 0.200 |
Why?
|
| Debridement | 2 | 2016 | 57 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 373 | 0.190 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.180 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.180 |
Why?
|
| Middle Aged | 17 | 2022 | 25863 | 0.180 |
Why?
|
| Ostomy | 2 | 2020 | 15 | 0.170 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 103 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 3657 | 0.170 |
Why?
|
| Sepsis | 1 | 2003 | 319 | 0.170 |
Why?
|
| Recurrence | 4 | 2021 | 1140 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2019 | 26 | 0.170 |
Why?
|
| Postoperative Period | 3 | 2021 | 301 | 0.170 |
Why?
|
| Risk Factors | 7 | 2022 | 5466 | 0.160 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 69 | 0.160 |
Why?
|
| Colitis | 1 | 2021 | 244 | 0.150 |
Why?
|
| Surgeons | 1 | 2022 | 247 | 0.150 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 573 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2018 | 158 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2017 | 72 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 345 | 0.140 |
Why?
|
| Aged | 8 | 2020 | 19077 | 0.140 |
Why?
|
| Sigmoidoscopy | 1 | 2016 | 36 | 0.140 |
Why?
|
| Blood Loss, Surgical | 3 | 2013 | 115 | 0.140 |
Why?
|
| Ileostomy | 2 | 2019 | 29 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2018 | 4273 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2015 | 865 | 0.130 |
Why?
|
| Intestinal Fistula | 1 | 2015 | 31 | 0.130 |
Why?
|
| Perineum | 1 | 2015 | 36 | 0.130 |
Why?
|
| Surgical Instruments | 1 | 2015 | 57 | 0.130 |
Why?
|
| Appendectomy | 1 | 2015 | 36 | 0.130 |
Why?
|
| Cost Savings | 1 | 2015 | 69 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2015 | 195 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Abdomen | 1 | 2015 | 122 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 85 | 0.120 |
Why?
|
| Pelvic Floor | 1 | 2015 | 85 | 0.120 |
Why?
|
| Enterococcus faecalis | 1 | 2015 | 54 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 88 | 0.120 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2014 | 18 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 191 | 0.120 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 30 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 2016 | 124 | 0.110 |
Why?
|
| Portal Vein | 1 | 2014 | 120 | 0.110 |
Why?
|
| Collagen | 1 | 2015 | 293 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2017 | 551 | 0.100 |
Why?
|
| Suture Techniques | 1 | 2013 | 140 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2015 | 385 | 0.100 |
Why?
|
| Incidence | 2 | 2014 | 1592 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 251 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2014 | 206 | 0.100 |
Why?
|
| Length of Stay | 2 | 2013 | 732 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 250 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2017 | 780 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 242 | 0.090 |
Why?
|
| Microbiota | 1 | 2016 | 398 | 0.090 |
Why?
|
| Time Factors | 3 | 2013 | 5320 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 233 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 52 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.080 |
Why?
|
| Cross Infection | 1 | 2010 | 146 | 0.080 |
Why?
|
| Prognosis | 4 | 2020 | 3773 | 0.080 |
Why?
|
| Reoperation | 3 | 2019 | 598 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2019 | 94 | 0.080 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2006 | 11 | 0.070 |
Why?
|
| Young Adult | 5 | 2019 | 6288 | 0.070 |
Why?
|
| src-Family Kinases | 2 | 2006 | 76 | 0.070 |
Why?
|
| Paxillin | 2 | 2006 | 59 | 0.070 |
Why?
|
| Illinois | 2 | 2019 | 472 | 0.070 |
Why?
|
| Propensity Score | 2 | 2018 | 147 | 0.070 |
Why?
|
| Remission Induction | 2 | 2019 | 740 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1400 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2020 | 2863 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2004 | 698 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1855 | 0.060 |
Why?
|
| Phenotype | 2 | 2022 | 2439 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 2004 | 49 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 786 | 0.060 |
Why?
|
| Fluconazole | 1 | 2003 | 10 | 0.060 |
Why?
|
| Peroxides | 1 | 2003 | 12 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2003 | 31 | 0.060 |
Why?
|
| Abdominal Cavity | 1 | 2003 | 18 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2003 | 34 | 0.060 |
Why?
|
| Laparotomy | 1 | 2003 | 67 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2004 | 268 | 0.060 |
Why?
|
| Colostomy | 1 | 2022 | 13 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 293 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 257 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 77 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2003 | 119 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 228 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2003 | 426 | 0.050 |
Why?
|
| Ligands | 1 | 2003 | 443 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 261 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 975 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 307 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 783 | 0.050 |
Why?
|
| Radiography | 1 | 2003 | 809 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 988 | 0.050 |
Why?
|
| United States | 3 | 2019 | 6955 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 1182 | 0.040 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 15 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 309 | 0.040 |
Why?
|
| Adolescent | 3 | 2019 | 9237 | 0.040 |
Why?
|
| Vitamin D | 1 | 2021 | 268 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 786 | 0.040 |
Why?
|
| Ileum | 1 | 2018 | 160 | 0.040 |
Why?
|
| Biological Products | 1 | 2019 | 151 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2019 | 279 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 859 | 0.040 |
Why?
|
| Medical Records | 1 | 2017 | 120 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 485 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 971 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 2001 | 0.030 |
Why?
|
| Dehydration | 1 | 2015 | 20 | 0.030 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 10 | 0.030 |
Why?
|
| Anus Diseases | 1 | 2015 | 15 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 280 | 0.030 |
Why?
|
| Models, Economic | 1 | 2015 | 62 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 682 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 107 | 0.030 |
Why?
|
| Endoscopy | 1 | 2018 | 348 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 217 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 302 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2015 | 129 | 0.030 |
Why?
|
| Mesenteric Veins | 1 | 2014 | 33 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 248 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 833 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 771 | 0.030 |
Why?
|
| Contrast Media | 1 | 2019 | 1090 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1837 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2013 | 11 | 0.030 |
Why?
|
| Rectal Diseases | 1 | 2013 | 24 | 0.030 |
Why?
|
| Ischemia | 1 | 2015 | 251 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1012 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 461 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2015 | 230 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 504 | 0.030 |
Why?
|
| Infliximab | 1 | 2013 | 159 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2290 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 1240 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 571 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1265 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1429 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 1423 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 2011 | 36 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 442 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1043 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2013 | 357 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2495 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1212 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 351 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1543 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 4040 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2552 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3373 | 0.020 |
Why?
|
| Detergents | 1 | 2006 | 34 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2006 | 33 | 0.020 |
Why?
|
| Tyrosine | 1 | 2006 | 133 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2004 | 7 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 65 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2004 | 54 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 91 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 92 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2004 | 213 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 289 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2006 | 665 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 432 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1130 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11737 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 465 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 27317 | 0.010 |
Why?
|